CHRM5

Muscarinic acetylcholine receptor M5 · P08912 · CHRM5 on Sugi Atlas →

225,897 patent compounds predicted against CHRM5, 128,732 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dimethindene (SCHEMBL18759)	1.00	19/20
Diphenidol (SCHEMBL34469)	1.00	10/20
Oxapium (SCHEMBL24857)	0.41	10/20
Oxotremorine (SCHEMBL2128)	1.00	6/20
Carbamoylcholine (SCHEMBL2791)	1.00	6/20
Carbamoylcholine (SCHEMBL2792)	1.00	6/20
Ipratropium (SCHEMBL3124)	1.00	6/20
Ipratropium (SCHEMBL3125)	1.00	6/20
Acetylcholine (SCHEMBL3216)	1.00	6/20
Acetylcholine (SCHEMBL40885)	1.00	6/20
Ipratropium (SCHEMBL3852)	0.98	6/20
Ipratropium (SCHEMBL3853)	0.98	6/20
Ipratropium (SCHEMBL3854)	0.98	6/20
Suxamethonium (SCHEMBL41536)	0.67	6/20
Xenytropium (SCHEMBL24707)	0.66	6/20
Hydrochloric Acid (SCHEMBL15954)	0.65	6/20
Suxamethonium (SCHEMBL41537)	0.65	6/20
Fentonium (SCHEMBL24583)	0.64	6/20
Fentonium (SCHEMBL24584)	0.64	6/20
SCHEMBL20908	0.56	6/20

Clinical trials — most relevant to CHRM5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia	PHASE4	COMPLETED
Anti-inflammatory Effects of Tiotropium in Patients with Stable COPD	PHASE4	COMPLETED
Galantamine for Cognition in People With Schizophrenia	PHASE4	COMPLETED
Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications	PHASE4	COMPLETED
Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause	PHASE4	COMPLETED
Postoperative Sugammadex After COVID-19	PHASE4	UNKNOWN
Metoclopramide as Treatment of Clozapine-induced Hypersalivation	PHASE3	COMPLETED
Galantamine for Cognitive Deficits in Schizophrenia	PHASE2/PHASE3	COMPLETED
Transcranial Magnetic Stimulation in Patients with Dual Disorders	PHASE3	NOT_YET_RECRUITING
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease	PHASE1/PHASE2	RECRUITING
Nicotinic Receptors and Schizophrenia	PHASE1/PHASE2	WITHDRAWN
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence	PHASE2	COMPLETED
A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma	PHASE2	COMPLETED
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response	PHASE2	COMPLETED
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition	PHASE2	RECRUITING
A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants	PHASE1	NOT_YET_RECRUITING
M1 Schizophrenia PET Study	PHASE1	COMPLETED
Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants	PHASE1	COMPLETED
The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine	PHASE1	WITHDRAWN
Cholinergic Mechanisms of Attention in Aging	EARLY_PHASE1	COMPLETED
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy	nan	COMPLETED
Mental Ability Challenge Study in Adults With and Without HIV	nan	COMPLETED
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine	nan	WITHDRAWN
Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers	nan	UNKNOWN
Brain Imaging in Depression	nan	COMPLETED
Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome	nan	COMPLETED
Cholinergic Status and the Metabolic Syndrome	nan	UNKNOWN
Brain Imaging in Elderly People and Individuals With Alzheimer's Disease	nan	COMPLETED
Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CHRM5 binder may also engage these)

Protein	Name	Similarity
Q5IS53	—	1.000	Q5IS53 →
P56490	—	1.000	P56490 →
Q920H4	—	1.000	Q920H4 →
Q9N2A4	—	1.000	Q9N2A4 →
Q5IS98	—	1.000	Q5IS98 →
P08911	—	1.000	P08911 →
P08483	—	1.000	P08483 →
Q9ERZ3	—	0.998	Q9ERZ3 →
Q9N2A3	—	0.997	Q9N2A3 →
P70174	—	0.995	P70174 →
P11483	—	0.993	P11483 →
Q9N2A2	—	0.992	Q9N2A2 →
P41984	—	0.992	P41984 →
CHRM3	Muscarinic acetylcholine receptor M3	0.991	landscape →
O46635	—	0.988	O46635 →
Q75Z89	—	0.987	Q75Z89 →
HRH1	Histamine H1 receptor	0.987	landscape →
Q9U7D5	—	0.987	Q9U7D5 →
P49578	—	0.985	P49578 →
HTR2C	5-hydroxytryptamine receptor 2C	0.985	landscape →
P30546	—	0.984	P30546 →
P31390	—	0.984	P31390 →
P18599	—	0.983	P18599 →
P31389	—	0.983	P31389 →
Q91175	—	0.983	Q91175 →
Q18007	—	0.982	Q18007 →
P97718	—	0.982	P97718 →
P56489	—	0.982	P56489 →
Q5IS66	—	0.982	Q5IS66 →
Q9N2B2	—	0.981	Q9N2B2 →